3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Carcinoma, Non-Small-Cell Lung
26
Parkinson Disease 4, Autosomal Dominant Lewy Body
21
Breast Neoplasms
17
Neoplasms
16
Multiple Myeloma
16
Leukemia, Myeloid, Acute
15
Recurrence
10
Colorectal Neoplasms
10
Myelodysplastic Syndromes
9
Lymphoma, Non-Hodgkin
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Leukemia
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Melanoma
7
Lymphoma, Follicular
7
Carcinoma, Renal Cell
7
Carcinoma, Hepatocellular
7
Stomach Neoplasms
6
Ovarian Neoplasms
6
Lymphoma, Large B-Cell, Diffuse
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Uterine Cervical Neoplasms
5
Purpura, Thrombocytopenic, Idiopathic
5
Neoplasm Metastasis
5
Lymphoma, Mantle-Cell
5
Lung Neoplasms
5
Graft vs Host Disease
5
Esophageal Neoplasms
5
Bronchiolitis Obliterans Syndrome
5
Adenocarcinoma
5
Interventions
enfortumab vedotin
1
avelumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Has announcements
×
Urologic Neoplasms
×
Clear all
NCT03219333
2024-08-27
EV-201
Astellas Pharma Inc
Phase 2
Completed
219 enrolled
32 charts
2 FDA
NCT02603432
2024-03-27
JAVELIN Bladder 100
Pfizer
Phase 3
Completed
700 enrolled
35 charts
1 FDA